Date: 2013-03-12
Type of information: Development agreement
Compound: companion diagnostic test for solid tumors
Company: LeicaBiosystems (Germany) Synthon Biopharmaceuticals (The Netherlands)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism:
Disease: solid tumors
Details: * On March 12, 2013, Leica Biosystems and Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, have announced an agreement to collaborate on the development and commercialization of a companion diagnostic test using the Leica BOND system, paired with one of Synthon Biopharmaceutical’s antibody-drug conjugates (ADCs), to enhance the treatment of solid tumors. This agreement provides framework for further collaboration projects. Leica’s work program will be lead from their new Companion Diagnostics Research and Development site in Danvers, Greater Boston,Massachusetts, with kit manufacturing occurring in Newcastle.
Financial terms:
Latest news:
